JPM 2021: EY Says Pandemic Leaves Medtech With $500Bn In M&A Firepower
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
You may also be interested in...
Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Teleflex Adds Hemostatic Products With $525M Acquisition Of Z-Medica
Z-Medica’s wound care products, led by its QuikClot Control+ hemostatic dressing, complement Teleflex’s existing line of products marketed to first responders and the military.
Integra Adds ACell’s Regenerative Tech As It Dumps Extremity Orthopedics
Integra will pay up to $400m for ACell to expand its wound management and soft-tissue repair product line. The deal is part of a larger restructuring plan that includes selling its orthopedics business.